The DESTINY-Breast06 trial evaluated fam-trastuzumab deruxtecan-nxki (T-DXd) in patients with hormone receptor (HR)-positive, HER2-low or -ultralow metastatic breast cancer after disease progression on endocrine-based therapy. Results were presented by Curigliano et al at the 2024 ASCO Annual Meeting (Abstract LBA1000).
